卡培他滨维持治疗转移性乳腺癌的疗效观察

Clinical observation of capecitabine maintain treatment on metastatic breast cancer

目的:观察卡培他滨维持治疗转移性乳腺癌的疗效和毒副反应。方法:2009年10月-2013年7月,31例转移性乳腺癌一线或二线含卡培他滨联合化疗4-6个周期后,疾病达缓解或稳定的患者,接受卡培他滨维持治疗,卡培他滨1000mg/m2,d1-14,休息7天,21天为1个周期,维持化疗进展或不能耐受毒副反应者化疗停止,每个患者接受至少2个周期维持治疗。结果:卡培他滨维持治疗转移性乳腺癌有效率(RR)为6.5%,临床获益率(CBR)(>6个月)为35.5%,疾病控制率(DCR)为74.2%,中位无进展生存期(PFS)为5.8个月。主要的毒副反应为手足综合征(HFS),发生率为67.7%,多为Ⅰ-Ⅱ度,1例Ⅲ度患者应用大剂量维生素B6且卡培他滨减量后好转。Ⅲ-Ⅳ度白细胞、中性粒细胞下降分别为9.7%和12.9%,明显低于卡培他滨联合化疗时Ⅲ-Ⅳ度白细胞、中性粒细胞下降发生率的35.5%和38.7%(P<0.05)。结论:卡培他滨是维持治疗转移性乳腺癌的有效药物,患者耐受性好,毒副反应较轻。

Objective：To obsere the effect and adverse reaction of capecitabine maintain treating metastatic breast cancer. Methods：During October 2009 to July 2013,31 cases of metastatic breast cancer patients were given the maintain treatment of capecitabine patients were given capecitabine 1000mg/m2, d1-14, rest 7 days. 21 days as 1 cy- cle,at least two cycles maintenance. Results：RR was 6.5% ,clinical benefit rate（CBR） （ 〉 6 months） was 35.5% , disease control rates（DCR） was 74.2%. The median progression- free surial（PFS） was 5.8 months. The main ad- verse reactions was hand -foot syndrome（HFS） incidence was 67.7% ,most were I - Ⅱ degrees, 1 case was Ⅲ de- gree. Ⅲ - IV degree white blood cells fell by 9.7 %, neutrophils fell by 12.9%, which were significantly lower than that of capecitabine chemotherapy in which the incidence rate were 35.5% and 38.7% （P 〈 0.05 ）. Conclusion： Capecitabine is effective on treating metastatic breast cancer. The adverse reaction is light.